Kornimate/medical-research-clean huggingface dataset:
evaluation of serum klotho as a predictor of progression of cardiovascular calcification in chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: this prospective observational study aims to investigate the relationship between cvc and serum klotho for renal function correction in patients with different ckd stages

in this study, we plan to enroll 400 non-dialysis patients with ckd 2-5 and 300 maintenance hemodialysis patients. participants will receive coronary artery computed tomography (ct) scanning to detect the extent and the severity of cvc. follow-up is scheduled at 0, 6, 12, 18, and 24 months and will consist the following: routine physical examinations, standard lab panels (blood routine, liver/kidney functions, tests of the coagulation system, etc.), total calcium, phosphate, parathyroid hormone (pth), serum 25(oh) vitamin d, fibroblast growth factor-23 (fgf-23) and coronary artery computed tomography (ct). the purpose of this study was to clarify the relationship between cvc in patients with different ckd stages and serum klotho for renal function correction, and to clarify that klotho can be used as an early biomarker for cvc in patients with ckd, so as to predict the occurrence and progress of cvc.

Eligibility criteria:
inclusion criteria: 1. age over 18 years old, regardless of gender 2. non-dialysis patients with ckd 2-5, or patients with ckd 5 under hemodialysis for more than 3 months exclusion criteria: 1. life expectancy \< 2 years 2. severe complications of heart, lung, liver or brain 3. primary hyperparathyroidism 4. malignant tumor 5. pregnant or breastfeeding 6. contraindications to ct examination 7. unwilling or unable to comply with the research protocol

Keywords: klotho cardiovascular calcification
study on the efficacy of las41005 in the treatment of actinic keratosis

Conditions: Actinic Keratosis

Summary: the purpose of this study is to investigate the efficacy of las41005 in comparison to placebo and to las106521 in actinic keratosis (ak).

to investigate as primary objective: * superiority to placebo and non-inferiority to las106521 measured by histological clearance of one predefined target lesion; to investigate as secondary objective: * superiority to las106521 * improvement of treated lesions (lesion response) * assessment of tolerability and safety by physicians global assessment score (pga, pgt) * patient's assessment of tolerability and efficacy and patient's compliance

Eligibility criteria:
main inclusion criteria: * have at least 4 but not more than 10 clinically confirmed ak target lesions of mild to moderate intensity within the face/forehead or bald scalp (excluding eyelids, lips, and mucosa), i.e. actinic keratosis grade i and ii according to olsen ea et al. 1991 * woman of childbearing potential are allowed to participate in this study only if they use a highly effective method of contraception main exclusion criteria: * have received effective treatment of ak in the three months preceding this clinical trial * have known hypersensitivity to las41005 or las106521 * have currently other malignant or benign tumors of the skin within the treatment area (e.g. malignant melanoma, basal cell carcinoma, squamous cell carcinoma) * patient's taking phenytoin * show cornu cutaneum like alterations of the skin in the face or the bald scalp (target area)

Keywords: actinic keratosis ak nmsc combination
efficacy and safety study of ingavirin® to treat influenza and acute respiratory viral infections in patients 13-17 y.o.

Conditions: Influenza, Human; Acute Respiratory Infection; Viral Infection; Common Cold

Summary: the purpose of this study is to determine whether ingavirin ® dosed 60 mg daily is effective and safe in the treatment of influenza and other acute respiratory viral infections in 13-17 years old patients.


Eligibility criteria:
inclusion criteria: * the informed consent form signed by the patient's parent/adoptive parent to participate in the clinical study * male and female patients aged 13-17 * patients with moderate course of influenza or other acute respiratory viral infections (avri) * patients with clinically diagnosed influenza or other arvi based on the body temperature \> 37,5 ° c, not less than 1 of the following other symptoms of intoxication and not less than 1 of the following of catarrhal symptoms: * intoxication symptoms: headache, malaise, myalgia, pain in the eyeballs; * catarrhal symptoms: sore throat, rhinorrhea, cough, nasal congestion * uncomplicated course of influenza and other arvi * interval between onset of symptoms and enrollment to the study of not more than 36 hours exclusion criteria: * complicated course of influenza and other acute respiratory viral infections * treatment with antiviral drugs (antivirals, interferons and interferon inducers), drugs with immunomodulatory effects or antibiotics with systemic and local action within 7 days prior to the screening visit * severe influenza or other arvi with symptoms of cardiovascular disease, and other symptoms of infectious-toxic shock, and meningoencephalitic syndromes * signs of primary viral pneumonia development (presence of two or more of the following symptoms): shortness of breath, chest pain when coughing, systemic cyanosis, dullness of percussion sound at symmetrical assessment of the upper and lower parts of the lungs * infectious diseases within the last week prior to enrollment * "rri children" (incidence of arvi within the last 12 months is 6 times or more) * asthma history * history of increased seizure activity * severe decompensated or unstable medical or psychiatric conditions (any diseases or conditions that threaten the life of the patient or worsen the patient's prognosis and also make it impossible to conduct a clinical study in the patient). * cancer, hiv infection, tuberculosis, including those in history * hypersensitivity to imidazolyl ethanamide pentandioic acid and/or excipients of ingavirin product * diabetes, lactose intolerance, lactase deficiency, glucose-galactose malabsorption, deficiency of sucrase/isomaltase, fructose intolerance, hereditary glucose malabsorption, deficiency of glucose-6-phosphate dehydrogenase * participation of the patient in any other clinical trial within the last 90 days prior to enrollment
multiple iv dose study of pf-04360365 in patients with mild to moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: purpose of the study is to determine whether multiple dose administration of pf-04360365 is safe and well tolerated in patient with mild to moderate alzheimer's disease.


Eligibility criteria:
inclusion criteria: * males or females of non childbearing potential, age \> or = 50 * diagnosis of probable alzheimer's disease, consistent with criterial from both: * national institute of neurological and communicable disease and stroke and alzheimer's disease and related disorders association (nincds-adrda) * diagnostic and statistical manual of mental disorders (dsm iv) * mini-mental status exam score of 16-26 inclusive * rosen-modified hachinski ischemia score of \< or = 4 exclusion criteria: * diagnosis or history of other demential or neurodegenerative disorders * diagnosis or history of clinically significant cerebrovascular disease * specific findings on magnetic resonance imaging (mri); cortical infarct, micro hemorrhage, multiple white matter lacunes, extensive white matter abnormalities * history of autoimmune disorders * history of allergic or anaphylactic reactions

Keywords: alzheimer's disease antibody amyloid
elastography in thyroid nodules

Conditions: Thyroid Nodule

Summary: thyroid nodules are a common finding in the general population,however, they are mostly unpalpable and usually discovered either during neck ultrasound (us) examination or by pathological examination at autopsy. they are found in about 8% of adults. most thyroid nodules ''incidentalomas" are benign, however 7% may be malignant. early detection of thyroid cancer helps in early treatment and better survival us is an accurate method for detection of thyroid nodules; however, us has a low accuracy in differentiating between benign from malignant thyroid nodules . us could suggest a malignancy likelihood criteria of a thyroid nodule, such as hypoechogenicity, increased intranodular vascularity, irregular margins, microcalcifications, absent halo, and a taller-than-wide shape measured in the transverse dimension.

us elastography has been used to detect the nature of thyroid nodules, by measuring the tissue stiffness non invasively. it depends on tissue deformation strain that is caused by external compression.it is complementary to gray scale findings particularly in nodules with indeterminate us findings, also us elastography could be used to guide the follow up of leisons diagnosed as benign at ( fna) fine needle aspiration . there are two main thyroid elastography methods in clinical practice: strain elastography (se) and shear-wave elastography (swe) . elastography methods can be classified into different variants based on the excitation method (external force, internal force, and acoustic radiation force \[arf\]), and how stiffness is expressed . (a) strain elastography . se reqires mechanical stress, which results in axial displacement of the tissue tissue deformation from the stress is measured and visualized on a screen. the main limitations of se are operator dependence for the angle, strength, and duration of compression. (b) shear wave elastography . the acoustic pulses from the probe stimulate the target tissue, creating a shear wave (sw) traveling perpendicular to the conventional us waves. sws are the transverse components of particle displacement that are rapidly attenuated by the tissue (1- 10 m/sec). this transverse component is tracked and measured as a numerical value corresponding to the shear-wave speed (sws).this speed is closely related to the young modulus formula, in which tissue elasticity can be assessed from the sw propagation. us elastography is completely painless for the patient, and only requires a few extra minutes, with no separate patient preparation. us elastography has the potential to distinguish benign from malignant tns, offering non-invasive complementary information to conventional us. it may be particularly useful in patients who have nondiagnostic or indeterminate fna cytology results.

Eligibility criteria:
inclusion criteria: * solitary nodule on clinical or ultrasound examination exclusion criteria: * patients received any medical treatment or chemo or radiotherapy. * patients underwent fine needle aspiration cytology or biopsy * nodules with calcification and cystic changes
effects of virtual reality versus motor imagery versus routine physical therapy in patients with parkinson's disease.

Conditions: Parkinson Disease

Summary: the aim of this study is to investigate the effects of vr and mi techniques in addition to routine physical therapy on motor skills, balance and adl in patients with parkinson's disease.

parkinson's disease is one of the most common, insidious neurological disorders with major motor symptoms, including bradykinesia, resting tremors, rigidity, and postural disorders. virtual reality and motor imagery are among the more innovative techniques for rehabilitation of patients with parkinson's disease that promote motor learning through both explicit and implicit processes.this study is unique in that it examines the effects of vr versus mi on motor skills, balance, and daily living activities in individuals with parkinson's disease

Eligibility criteria:
inclusion criteria: * idiopathic parkinson's disease * modified hoehn and yahr scale(h\&y stages i to iii) * between the ages of 50 and 80 years of both genders * independent in transfers * a score equal to or greater than 24 on the mini-mental state examination (mmse), and * previous lack of participation in balance or motor training. exclusion criteria: * history of any neurological conditions such as stroke, multiple sclerosis, epilepsy other than parkinson's disease, * history of orthopedic issues such as pain, fracture, or lower limb pathology, * history of visual abnormalities, * history of any chronic or cardiovascular pathology that can interfere with the transfer procedure or can affect the training sessions, * the participants having severe dyskinesia or "on-off" phases, * previous history of surgery for pd, * history of virtual games used for treatment in the past three months, and * virtual game phobia.

Keywords: parkinson virtual reality motor imagery routine physical therapy
comparison of fixation suture type in glaucoma surgery

Conditions: Glaucoma Eye; Glaucoma

Summary: the aim of the study is to compare the effectiveness and safety of two types of intraoperative eye fixation: for the superior rectus muscle and traction suture in the peripheral cornea. this is a prospective randomized trial with a 6 month follow-up period, which covers patients with open angle glaucoma qualified for combined glaucoma procedure (phacotrabeculectomy). in i group, the intraoperatively fixation in the peripheral part of the cornea is used, in ii group the bridle suture for the superior rectus muscle is performed.

the way of the intraoperatively fixation may have some impact for postoperative results of the level of intraocular pressure (iop), visual acuity (bcva) and the incidence of upper eyelid ptosis was determined as a post-operative mrd (margin reflex distance) ≥2mm.

Eligibility criteria:
inclusion criteria: * co-existing glaucoma and cataract (nc1, nc2) classified by means of the locs iii scale (lens opacities classification system iii) * primary open-angle glaucoma and secondary pseudoexfoliative glaucoma, in which a satisfactory iop level was not achieved despite maximum tolerable hypotensive treatment, both topical and systemic * documented progression of loss of field of vision * significant daily iop fluctuations * no cooperation from patient with regard to application of anti-glaucoma treatment, allergy to topical medications exclusion criteria: * no consent to participation in the study * prior surgical and laser procedures in the area of the eye * narrow- or closed-angle glaucoma * post-inflammatory or post-traumatic secondary glaucoma * chronic illness of the cornea or optic nerve * advanced macular degeneration * active inflammatory process * pregnancy * systemic steroid therapy

Keywords: ptosis combined procedures glaucoma post-surgery complication
evaluation of an anti-shivering protocol cardiac arrest

Conditions: Cardiac Arrest

Summary: this will be a single center, retrospective, before-and-after, chart review of all patients undergoing ttm between june 1, 2017 and may 31, 2021 at mdmc. initiation of the new ttm protocol occurred on april 22, 2019.

this will be a single center, retrospective, before-and-after, chart review of all patients undergoing ttm between june 1, 2017 and may 31, 2021 at mdmc. initiation of the new ttm protocol occurred on april 22, 2019. to allow for an adequate washout period, patients who were initiated on ttm before april 22, 2019 will be in the "before" group and patients initiated on ttm on or after june 1, 2019 will be in the "after" group. patients will be identified based on electronic medical records search of order sets utilized in ttm and confirmed with manual chart review. statistical analysis will be performed as detailed below.

Eligibility criteria:
inclusion criteria: * age \> 18 years * diagnosis of cardiac arrest * initiation of ttm via arctic sun® device exclusion criteria: * initiation of ttm \> 12 hours after cardiac arrest * receiving nmbs for an indication other than ttm * early termination of ttm (less than 24 hours)
utility of upper-extremity plyometrics in children with unilateral cerebral palsy

Conditions: Cerebral Palsy

Summary: this study was set out to evaluate the effect of a 12-week upper extremity plyometric exercise (plyo-ex) on muscle strength and upper extremity function in children with hemiparetic cerebral palsy (hemi-cp). fifty-eight children with hemi-cp were randomly allocated to the plyo-ex group (n = 29, received plyo-ex program, twice/week, over 12 weeks) or the control group (n = 29, received standard exercise program). both groups were assessed for muscle strength and upper extremity function before and after treatment.

fifty-eight children with hemi-cp were recruited from the physical therapy outpatient clinic of prince sattam bin abdulaziz university and three referral hospitals in riyadh provenience, saudi arabia. their age ranged between 10 and 15 years, were functioning at levels i or ii according to the gross motor function classification system, and had spasticity levels 1 or 1+ per the modified ashworth scale. children were excluded if they had fixed deformities, underwent neuromuscular or orthopedic surgery in the last 12 months, submitted to botox injection in the past 6 months, had attentional neglect, demonstrated any cognitive issues, and if they had cardiopulmonary problems that could be exacerbated by exercise. outcome measures muscle strength: the peak isometric muscle strength of the shoulder flexors, abductors, external rotators, elbow extensors, and wrist extensors was measured using a hand-held dynamometer. unilateral upper-extremity function : the unimanual functional performance was assessed using melbourne assessment (ma). bimanual hand function:the biimanual functional performance was evaluated utilizing the assisting hand assessment (aha) the plyo-ex group received a 12-week therapist-led plyo-ex training, for approximately 45 minutes per session, two times a week for 12 consecutive weeks, in conformity with the national strength and conditioning association guidelines and american academy of pediatrics safety standards. the plyo-ex program consisted of ten unilateral and bilateral upper extremity exercises in the form of push-ups and ball slams/throws/passes activities. the plyo-ex program preceded with a warm-up for 5 minutes and ended with a cool-down for 5 minutes. the control group received the standard exercise program, 45 minutes per session, two times a week for 12 consecutive weeks. the program consisted of flexibility exercises, strength training, weight-bearing exercises, proprioceptive neuromuscular facilitation, coordination exercise, task-oriented training, and functional exercises.

Eligibility criteria:
inclusion criteria: * unilateral cerebral palsy * age 10-15 years * motor function level i or ii according to the gross motor function classification system. * spasticity level 1 or 1+ according to the modified ashworth scale exclusion criteria: * structural deformities/contractures * musculoskeletal or neural surgery in the last year * botox injection in the last 6 months. * cardiopulmonary disorders that could be exacerbated by exercise. * perceptual and/or behavioral disorders.
predictive toxicity test linked to radiotherapy after mastectomy and immediate implant reconstruction

Conditions: Breast Cancer; Capsular Contracture Associated With Breast Implant

Summary: this study evaluates the capacity of the novagray rila breast® test to predict the toxicity linked to radiotherapy and the impact of implant breast reconstruction.

immediate reconstruction after mastectomy may help women with breast cancer to deal with their fear of mastectomy, spare them one or more second surgery and additional hospital stays in case of late breast reconstruction. however, in france, most patients with invasive breast carcinoma and treated with mastectomy are not offered immediate reconstruction. one reason is the need for postoperative radiotherapy for most patients (40 to 70% according to the centers). indeed, radiotherapy induces side-effects which can alter the cosmetic result of the breast reconstruction as well as the patient's quality of life. since 1995, a significant correlation is observed between the rila test (measurement by flux cytometry of the lymphocyte t-cd8 apoptosis induced by radiotherapy) and the risk of occurrence of severe radio-induced breast fibrosis. such accurate personalized medical care could allow identifying before any treatment high risk of toxicity patients and thus help establishing the therapeutic strategy. identification of low-risk patients could also allow limiting autologous samplings and thus their associated morbidity.

Eligibility criteria:
inclusion criteria: * age ≥18 years * patients with histologically confirmed breast cancer with indication of mastectomy or surgery with mastectomy performed * indication of wall chest radiation after mastectomy * patient's agreement to receive or having had an immediate breast reconstruction by implant in one or two steps, with or without a dermal or synthetic matrix (depending on the habits of the center) * performance status 0-1 * consent signed before any study procedure * patient geographically accessible for follow-up * affiliated to the french national social security system exclusion criteria: * breast reconstruction with flap * inflammatory breast cancer (ct4d) * skin or parietal breast cancer (ct4 a, b or c) * metastatic patients * patients with bilateral breast cancer * history of homolateral breast cancer treated with radiotherapy * history of contralateral breast cancer * pregnant or breastfeeding women * legal incapacity or physical, psychological or mental status interfering with the patient's ability to sign the informed consent * participation in an interventional clinical study or planned participation during study up to 12 months post-radiotherapy
dietary patterns and health outcomes (cardiovascular, metabolic, endocrine, neurological, skeletal muscular, cancer)

Conditions: Cardiovascular Diseases; Cerebrovascular Disorders; Metabolic Disease; Neoplasms; Endocrine System Diseases; Neurologic Symptoms; Skeletal Anomalies; Diabetes Mellitus; Pregnancy Complications

Summary: to study, prospectively, the association between dietary patterns and risk of health outcomes (cardiovascular, metabolic, endocrine, neurological, skeletal muscular, cancer) in cohort study of 116,671 women age 24 to 44 years at baseline in 1989 (the nurses' health study ii; nhs ii).

health status and lifestyle information was self-reported on a questionnaire at baseline, and on questionnaires distributed to participants biennially thereafter. dietary intake data was collected in form of a comprehensive, 131-item food frequency questionnaire (ffq), distributed among participants every four years. the response rate remained over 90%. dietary data was validated using biomarkers, health status data using medical records. dietary pattern scores were derived from ffqs using cumulative average whenever possible from years preceding the outcomes. multivariable cox proportional hazards models were used to evaluate associations between dietary pattern scores and health outcomes, except in case of pregnancy complications (such as gestational diabetes mellitus/gdm and hypertensive disorders of pregnancy/hdps) where multivariable logistic regression models with generalized estimating equations, with an exchangeable working correlation structure to account for correlated outcomes between pregnancies.

Eligibility criteria:
inclusion criteria: * all women without history of chronic disease and/or primary outcome at the time of recruitment. women contribute person-time until a first diagnosis of the primary outcome or until the end of follow-up. * all women who reported a singleton pregnancy between 1991-2001 (data on pregnancy outcomes was collected on biennial questionnaires until 2001, since majority of women exited the reproductive age by then) (only for maternal outcomes) exclusion criteria: * women with a history of chronic disease (type 2 diabetes, cardiovascular disease, or cancer) or other disease studied as the primary outcome * women with a missing or incomplete ffq (more than 70 out of 131 items missing, or with caloric intake \ 3500kcal/day) prior to endpoint. * women with missing data on the primary outcome on biennial questionnaire. * twin/multiple pregnancy (only for maternal outcomes)